• Home
  • Search Results

Research Studies

UNC-Chapel Hill Lineberger Comprehensive Cancer Center

241 studies match your search
Open

Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers

If you have Testosterone-driven Salivary Gland Cancer, you may be able to participate in a research study testing the anti-cancer drug Darolutamide.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Head and Neck)
Not currently enrolling

A071701 Genomically-guided treatment trial in brain metastases

The purpose of this study is to test good and bad effects of different drugs against metastatic brain tumors with altered genes. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in patients such as you. Researchers have looked at the DNA material (genes) that can be affected in brain metastases and have found several genes that are altered, or mutated. There are medications that target these genes. We are doing this study because we want to find out if this approach is better or worse than the usual approach for your metastatic cancer. The usual approach is defined as care most people get for your metastatic cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Brain and Other Nervous System)
Open

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors

Have you been diagnosed with Prostate, Bladder, or Kidney Cancer? If so, you may be able to take part in a research study investigating the optimal way to combine or sequence therapies in patients with Rare Genitourinary Tumors.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Kidney)
  • Urinary and Bladder
Open

Safety, Efficacy, and Mechanism of Pre-operative Spatially Fractionated GRID Radiation Therapy in Patients with Extremity Soft Tissue Sarcoma: A Pilot Study

Have you been diagnosed with extremity soft tissue sarcoma and are scheduled to have standard of care radiotherapy (XRT) followed by surgery to treat your cancer? XRT is effective in managing extremity soft tissue sarcoma, however, it is associated with risks, such as damage to healthy tissue, and complications in post-surgery wound healing.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Sarcoma (bone and soft tissue))
Open

Radiation Therapy and Dry Mouth Study

Did you have head or neck cancer? Have you completed radiation in the past 3 years or more and now have dry mouth? You may be able to take part in a research study to help us learn if a gene therapy can help people with dry mouth due to radiation therapy.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Head and Neck)
  • Ear, Nose, and Throat
Open

Endometrial Cancer Study

Do you have grade 1 or 2 edometrioid endometrial cancer? You may be able to take part in a study to learn more about and test a new drug.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Uterine (endometrial))
  • Women's Health
Open

An Open-label, Multicenter Study of LOXO-435 in Advanced Solid Tumor Malignancies with FGFR3 Alterations

Have you been diagnosed with cancer and either your cancer did not respond to treatment or your cancer progressed? If so, you may be able to take part in a research study evaluating the safety of an investigational treatment called LOXO-435 in cancer patients.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Other Cancers)
Open

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Do you have endometrial cancer? ]. If so, you may be able to take part in a research study looking at the safety of giving a combination treatment of the drugs ONC201 plus Atezolizumab to patients with endometrial cancer.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Uterine (endometrial))
Not currently enrolling

Extensive Stage Small Cell Lung Cancer Study

The purpose of this study is to learn more about how an investigational drug (tarlatamab) works in people with extensive-stage small cell lung cancer. In this study, we want to learn more about its safety and tolerability (effects good or bad) when used in combination with one of two other drugs (atezolizumab or durvalumab). We also want to learn more about the combination of the study drug with either atezolizumab or durvalumab and carboplatin and etopopside.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lung, Phase 1 Trials (all cancers))
Open

HER2-positive breast cancer (ADEPT)

Have you been diagnosed with HER2 positive (HER2+) breast cancer and have recently or plan to undergo surgery? If so, you may be able to take part in a research study looking at the safety of giving two drugs trastuzumab and pertuzumab in combination with hormonal therapy after surgery for your breast cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research